|
Characteristics
|
# of cases (%)
|
ER+/Her2-
|
|---|
|
Low lng1
|
High lng1
|
P-value
|
|---|
|
Age
| | | | |
|
< 53
|
72 (16.25)
|
56
|
16
|
0.880
|
|
≥ 53
|
371 (83.75)
|
284
|
87
|
|
Menopausal status
| | | | |
|
Pre-menopausal
|
26 (5.90)
|
17
|
9
| |
|
Peri-menopausal
|
21 (4.70)
|
18
|
3
|
0.231
|
|
Post-menopausal
|
321 (72.50)
|
242
|
79
|
|
n/a (male)
|
1 (0.20)
|
1
|
0
|
|
Unknown
|
74 (16.70)
|
62
|
12
|
|
Stage
| | | | |
|
I
|
188 (42.40)
|
148
|
40
|
0.365
|
|
II
|
138 (31.20)
|
105
|
33
|
|
III
|
36 (8.20)
|
24
|
12
|
|
IV
|
5 (1.10)
|
3
|
2
|
|
Unknown
|
76 (17.20)
|
60
|
16
|
|
Tumor grade
| | | | |
|
1
|
103 (25.40)
|
88
|
15
|
0.001
|
|
2
|
247 (60.80)
|
195
|
52
|
|
3
|
56 (13.80)
|
31
|
25
|
|
Tumor size
| | | | |
|
< 2 cm
|
223 (53.86)
|
179
|
44
|
0.020
|
|
≥ 2 cm
|
191 (46.14)
|
137
|
54
|
|
Lymph node status
| | | | |
|
Negative
|
278 (72.77)
|
220
|
58
|
0.103
|
|
Positive
|
104 (27.23)
|
74
|
30
|
|
Rx Tamoxifen
| | | | |
|
No
|
161 (37.44)
|
118
|
43
|
0.196
|
|
Yes
|
269 (62.56)
|
212
|
57
|
- The listed clinico-pathological characteristics were analyzed for their correlation with low/high levels of stromal ING1. Stromal ING1 shows a correlation with tumor grade and size in the ER+/ Her2- group of patients in the cohort
